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Abstract: Each human's genome is distinguished by extra and missing DNA that can be “benign” or powerfully impact 
everything from development to disease. In the case of genomic disorders DNA rearrangements, such as deletions or du-
plications, correlate with a clinical specific phenotype. The clinical presentations of genomic disorders were thought to re-
sult from altered gene copy number of physically linked dosage sensitive genes. Genomic disorders are frequent diseases 
(~1 per 1,000 births). Smith-Magenis syndrome (SMS) and Potocki-Lupski syndrome (PTLS) are genomic disorders, as-
sociated with a deletion and a duplication, of 3.7 Mb respectively, within chromosome 17 band p11.2. This region in-
cludes 23 genes. Both syndromes have complex and distinctive phenotypes including multiple congenital and neurobehav-
ioral abnormalities. Human chromosome 17p11.2 is syntenic to the 32-34 cM region of murine chromosome 11. The 
number and order of the genes are highly conserved. In this review, we will exemplify how genomic disorders can be 
modeled in mice and the advantages that such models can give in the study of genomic disorders in particular and gene 
copy number variation (CNV) in general. The contributions of the SMS and PTLS animal models in several aspects rang-
ing from more specific ones, as the definition of the clinical aspects of the human clinical spectrum, the identification of 
dosage sensitive genes related to the human syndromes, to the more general contributions as the definition of genetic lo-
cus impacting obesity and behavior and the elucidation of general mechanisms related to the pathogenesis of gene CNV 
are discussed. 
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INTRODUCTION 
  Genomic structural changes, such as gene Copy Number 
Variations (CNVs) are extremely abundant among pheno-
typically normal human individuals [1, 2]. CNV are present 
in a large proportion of the human genome and include hun-
dreds of genes [3]. Currently over 19,000 human CNVs from 
approximately 6,200 regions (CNVRs) have been identified, 
ranging from 1kb to several megabases in size (http:// 
projects.tcag.ca/variation/). They are recognized important 
mutational mechanisms involved in several phenotypes that 
range from “normal” variability between individuals, suscep-
tibility to traits, genome evolution, to specific human ge-
nomic disorders [4-13].  
  Genomic disorders are the pathological evidence of CNV 
and they are frequent conditions, ~1 per 1,000 births [14]. If 
the rearrangements are large enough to be visualized by cy-
togenetic techniques and comprise multiple unrelated con-
tiguous genes they are named contiguous gene syndromes 
(CGS). Extensive studies have identified several CGS and 
despite the intra-patient variability, each CGS is defined by 
specific and complex phenotypes that can include neurobe-
havioral traits and congenital abnormalities [15-18] among 
other clinical presentations. The molecular mechanism   
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prevalent for the generation of the genomic rearrangements 
related with CGS is nonallelic homologous recombination 
(NAHR) or unequal crossing over, between flanking low-
copy number repeats (LCRs) [19-23], and thus the vast ma-
jority of patients with any given CGS harbor a common rear-
rangement encompassing a specific genomic interval.  
  The beauty of studying CGS is that there is a confined 
genomic interval that corresponds with a particular set of 
symptoms. Moreover, due to the mechanism by which most 
of the genomic rearrangements are generated it is frequent 
that given a specific CGS related to a deletion there will be 
another related to the reciprocal duplication. 
  Numerous new technologies were available within the 
last decade that allowed the assessment of CNVs within the 
genome, the molecular basis of mechanisms implicated in 
CNV generation, the discovery and study of CGS, the phe-
notypic outcome of a defined CGS, and the correlation be-
tween gene and phenotype. Among these new technologies 
the development and phenotypic assessment of mouse mod-
els for CGS have extensively contributed to this knowledge 
[24, 25]. 
SMITH-MAGENIS (SMS) AND POTOCKI-LUPSKI 
(PTLS) SYNDROMES  
  SMS (OMIM#182290) and PTLS (OMIM#610883) rep-
resent reciprocal CGS, associated with a deletion and dupli-
cation of a 3.7 Mb genomic interval within chromosome 17 260    Current Genomics, 2009, Vol. 10, No. 4  Carmona-Mora et al. 
band p11.2, respectively, each having a specific clinical 
presentation. The SMS, has an estimated prevalence of 
1/25,000 births. Whereas a commonly deleted region of ~3.7 
Mb is present in the majority of SMS patients (>70-80%) 
[26-28], an ~1.1Mb SMS critical region was defined that 
includes 15 previously identified genes and eight predicted 
genes [29-31]. Recently, haploinsufficiency of the Retinoic 
Acid Induced gene (RAI1), that is located within the critical 
genomic interval, was associated with most features of SMS 
[32-35]  suggesting that it  is the dosage sensitive gene re-
sponsible for SMS.  
  Phenotypes in SMS patients are well characterized, and 
they are summarized in Table 1. Clinical presentation of 
SMS includes obesity, craniofacial abnormalities and bra- 
chydactyly. Furthermore SMS patients show neurobehav-
ioral phenotypes that comprise self-injurious and maladap-
tive behaviors, speech delay, sleep disturbances, learning 
difficulties and a mild to moderate range of mental retarda-
tion and seizures [36-49].  
  Duplication of the SMS region, resulting in the PTLS, 
has been reported by Potocki et al., initially describing seven 
patients [50]. Further studies redefined the clinical spectrum 
[51, 52] and narrowed to 1.3 Mb the critical interval respon-
sible for the PTLS, this interval contains the RAI1 gene [52]. 
The PTLS clinical phenotype includes developmental delay, 
mental retardation, developmental deficit for psychomotor 
and expressive speech, autistic features, obsessive-com- 
pulsive behaviors and attention deficit. Other clinical find-
ings in PTLS patients encompass hypotonia, feeding difficul-
ties in infancy, failure to thrive and EEG abnormalities   
(Table 1). The dosage sensitive gene(s) responsible for PTLS 
remains unidentified; however, it was possible to demon-
strate that CNV of the Rai1 gene is mostly responsible for 
complex physical and behavioral traits in a mouse model for 
PTLS [53]. 
DIFFERENT MOUSE MODELS FOR SMS AND PTLS 
  The mouse shares physiologic, anatomic and genomic 
similarities with humans and can be genetically manipulated 
[54]. It has thus become an important animal model for 
studying human disease. Moreover, the completion of the 
human and mouse genomes sequences enables comparative 
genomic analyses, being relatively simple to see the feasibil-
ity of the generation of a mouse model for a CGS since for 
this purpose aspects as the synteny of the genomic region 
and the order and orientation of the genes are essential in-
formation. 
  Depending on the original situation or question that 
needs to be addressed different mouse models for CGS can 
be developed as is summarized in Fig. (1). If the dosage sen-
sitive gene is unknown but a critical genomic region is de-
fined a genomic rearrangement (deletion or duplication) can 
be generated within the mouse genome. On the other hand, if 
the dosage sensitive gene is known a knock-out/knock-in or 
overexpressing transgenic mouse can be produced.  
    For the generation of chromosomal deletions, duplica-
tions, inversions and translocations in mice there are many 
methodologies described [55-58]. The common disadvantage 
of all these technologies is that the rearrangements are gen-
erated at random. However, we will focus in the strategy that 
have been developed to introduce defined chromosomal rear-
rangements in the mouse genome by engineering them in 
embryonic stem cells (ES cells) using the Cre-loxP site-
specific recombination system [59, 60]. To generate a spe-
cific genomic rearrangement between two endpoints, two 
sequential gene-targeting steps are required in order to pre-
pare each endpoint for selectable Cre-loxP  recombination 
[59]. The double-targeted ES cell is then transiently trans-
fected with Cre recombinase (an enzyme that catalyzes site 
specific recombination between the specific 34 bp loxP sites) 
that facilitates the recombination between the two loxP sites, 
achieving the corresponding genomic rearrangement. The 
type of chromosome rearrangement obtained will be a direct 
consequence of the relative initial loxP configurations. If the 
loxP sites are in the same or direct orientation, the region 
between them will be deleted or duplicated. If the two loxP 
sites are inverted or in opposite orientation, the genomic re-
gion between them will be inverted [61-63]. Another versa-
Table 1.  Phenotypes Present in SMS and PTLS Patients and in their Respective Mouse Models 
Phenotype SMS  Df(11)17/+  PTLS  Dp(11)17/+ 
Body Weight  Elevated Overweight Reduced Underweight 
Craniofacial/Skeletal  Abnormal Abnormal Abnormal  Normal 
Speech  Delay, “Horse voice”  ND  Altered  ND 
Overt Seizures  Present (~20%)  Present (~20%)  Absent  Absent 
EEG  Abnormal   Abnormal  Abnormal  Normal 
Locomotor Activity Levels  Motor  delay Hypoactive Hyperactive Hyperactive 
Main Behavior Abnormality  Self injurious  Normal  Autistic   Social abnormalities  
Learning and Memory  Mental retardation  Normal learning and memory   Mental retardation  Abnormal learning and memory 
Pain Sensitivity  Decrease Normal  Normal  Normal 
Sleep  Abnormal   Abnormal circadian period  Normal  Normal Mouse Models of Genomic Syndromes  Current Genomics, 2009, Vol. 10, No. 4    261 
tility of this methodology is the possibility to choose the de-
sired endpoints, with the extra advantage of the availability 
of two complementary libraries (the 5’Hprt library and the 
3’Hprt library) for the initial targeting events [60]. Actually, 
the Mouse Genomics – MICER project: Mutagenic Insertion 
and Chromosomal engineering resource (http://www.sanger. 
ac.uk/PostGenomics/mousegenomics/) offers this resource 
openly, it provide vector sequences, chromosomal location 
and orientation of the insertion, and information on using 
MICER vectors for generating knock-out mice, and for 
chromosome engineering purposes [64]. 
  The above described technique was utilized to generate 
the SMS and PTLS mouse models. Human chromosome 
17p11.2 is syntenic to the 32-34 cM region of murine chro-
mosome 11. The number and order of the genes are highly 
conserved [29-31] (Fig. (2)). In the case of SMS and PTLS 
mouse models to generate the chromosomal rearrangements 
that include the common (syntenic)  deletion region, Csn3 
was selected as the proximal anchor point for one loxP site 
and Zfp179 was selected as the distal anchor point in murine 
chromosome 11. These two loxP sites were sequentially in-
serted with chromosome-engineering cassettes by gap repair 
recombination [60] into both anchoring points that  are lo-
cated approximately 3 Mb apart [30]. Double-targeted  ES 
cells were then subjected to Cre-mediated site-specific  re-
combination, and the ES cells carrying rearrangements were 
selected in HAT media by virtue of the reconstituted Hprt 
gene. In one ES cell clone both rearrangements, a deletion 
(Df(11)17) and a duplication (Dp(11)17) syntenic to the 
SMS critical region were obtained. Chimeric mice were pro-
duced and in the F1 mice heterozygous for the deletion: 
Df(11)17/+ (the SMS mouse model) and mice heterozygous 
for the duplication: Dp(11)17/+  (the PTLS mouse model) 
were segregated [65]. 
  Another methodology that derives from the described 
above is the generation of nested deletions in ES cells by 
chromosome engineering mediated by retrovirus infection 
and insertion of one of the loxP sites in a random fashion 
[66]. In this case a single gene, Csn3, was utilized as the 
anchoring point by targeting it with a vector containing the 
loxP site, the 5’ Hprt and the neomycin resistance gene fol-
lowed by an infection with retrovirus in order to introduce 
another  loxP site, with the second half of Hprt gene and 
puromycin resistance gene, for selecting infected cells with 
this antibiotic. Again, by transfecting the selected cells with 
a Cre-recombinase if the specific recombination takes place 
the cells can be selected in HAT medium. As the integration 
of loxP sites is at random, the deletions need to be character-
ized by FISH, southern blot, and PCR to trace the viral DNA 
and the size of deletions. Three independent deletions were 
obtained by this methodology for the SMS region named: 
Df(11)17-1, Df(11)17-2 and Df(11)17-3, all of them been 
smaller than the Df(11)17 [67]. 
  In 2003, the first reports on SMS patients not harboring 
the common deletion in 17p11.2, but carrying mutations in 
the RAI1 gene appeared [32-34]. This fact pointed to RAI1 as 
the dosage sensitive gene within this genetic interval. In or-
der to generate a mouse lacking one active allele of Rai1 the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Steps to consider when modeling genomic disorders in mice. A graphic representation of the steps to follow when deciding to 
generate a mouse model for CGS is presented. Different strategies could be followed depending if the dosage sensitive gene is known or 
unknown. Multiple advantages can be obtained with the different models as listed in the figure. 262    Current Genomics, 2009, Vol. 10, No. 4  Carmona-Mora et al. 
disruption of its coding region was achieved by the in frame 
insertion in the exon 2, or knock–in, of the coding sequence 
of E. coli lacZ gene plus a neoR expression cassette [68]. On 
the other hand, a transgenic mouse carrying extra copies of a 
BAC containing the Rai1 gene (RP23-326M22, GenBank 
accession AC096624) was generated [69]. Important is to 
note that this BAC clone contained not only the entire Rai1 
gene but also the complete Srebp1 gene sequence plus the 
3´end of the Tom1l2 gene in different number of copies that 
ranged from 4 to 5.  
  The summary of the different mouse models available for 
SMS and PTLS is represented in Fig. (3).  
LESSONS FROM THE MICE  
  Chronologically, the first SMS and PTLS mouse models 
to be generated and phenotypically assessed were the mice 
harboring the deletion and the duplication of the critical re-
gion,  Df(11)17/+  and  Dp(11)17/+, respectively [65]. The 
Df(11)17/+ mice displayed several characteristics present in 
SMS patients (Table 1). Obesity was observed in these mice 
beginning to be markedly overweight when compared to the 
wild type littermates at fourth months of age; consistently, 
abdominal fat contents were significantly higher in these 
animals. Craniofacial abnormalities were also observed, pre-
senting shorter overall skulls and broader and shorter snouts 
and nasal bones than the wild type mice. Df(11)17/+ mice 
exhibit overt seizures (~ 20%), in concordance with the hu-
man phenotype. Moreover, an abnormal EEG pattern was 
detected in these mice, as well as in patients EEG records 
that were revised due to the mouse phenotype [45]. 
Df(11)17/+ male mice were found to be hypoactive in the 
open field test as indicated by a significant decrease of the 
total distance traveled and time spent moving in the open 
field when compared to the wild type littermates. Sleep dis-
turbances are a main characteristic present in the SMS pa-
tients. Df(11)17/+ mice displayed a significantly shorter cir-
cadian period length than their wild types littermates (~27 
min) when they were tested in the twenty-four hour wheel 
running activity test in constant darkness. More interesting 
was the finding that the period length distribution among 
Df(11)17/+ mice was much more variable than among wild 
type mice, which may indicate a reduced precision of the 
clock control of period length associated with haploinsuffi-
ciency of genes in this defined genomic interval [70].  
  The mouse model for PTLS, Dp(11)17/+ mice, also pre-
sent physical characteristics of the human condition, as low 
corporal weight, concomitant with a significant reduction of 
abdominal fat content. Dp(11)17/+ mice presented hyperac-
tivity as indicated by a total significant increment in the dis-
tance traveled and the time spent moving in the open field 
when compared to the wild type mice. Increased anxiety 
behavior was observed for Dp(11)17/+ mice in the light-dark 
exploration test and in the plus maze test as indicated by a 
significant decrease in the number of light-dark transitions 
[70] or a time spent in the open arm [71] respectively. The 
conditioned fear test to assay a fear-based response using a 
Pavlovian learning and memory paradigm was used in 
Dp(11)17/+ mice and they presented an impaired condi-
tioned fear that was selective to the context test, and was 
present following both a 1 h and 24 h delay interval, indica-
tive of a short term memory deficiency [70]. PTLS patients 
present autistic characteristics, in agreement with this 
Dp(11)17/+ mice showed an abnormal social behavior when 
tested in the three chamber test for sociability or preference 
for social novelty [72] or the tube test (a paradigm previ-
ously found to be useful in predicting impairments in social 
interaction [71, 73, 74]. In summary, the Df(11)17/+  and 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic representation of the SMS and PTLS genomic region. Representation of the 17p11.2 region of human chromosome 
17 and its syntenic counterpart region 32- to 34-cM of the mouse chromosome 11 is depicted [53]. Centromeres are represented in gray cir-
cles. Note that the numbers, orientations, and relative orders of the genes in these syntenic genomic intervals are extremely conserved. Three 
low-copy repeats are present in the human region: SMS-REPD (distal); SMS-REPM (middle); SMS-REPP (proximal). Mouse Models of Genomic Syndromes  Current Genomics, 2009, Vol. 10, No. 4    263 
Dp(11)17/+ mice are well characterized and represent vali-
dated models for further studies (Table 1).  
  When mice with smaller deletions (Df(11)17-1, Df(11)- 
17-2 and Df(11)17-3) [67] were phenotypically characterized 
they also showed obesity and craniofacial abnormalities, but 
it was reported that the penetrance of the craniofacial pheno-
type was markedly reduced, strongly suggesting that other 
genes or regulatory elements influence in the penetrance of 
the phenotype. The genomic fragment that is different be-
tween the critical deletion (Df(11)17) and the shorter dele-
tion that was analyzed in this paper was ~ 2.500 kb, compris-
ing 14 genes, narrowing down the modifiers candidates 
genes.  
 When  the  Rai
+/- mouse were analyzed obesity and cranio-
facial abnormalities were observed [68] corroborating that 
these two phenotypes are a direct consequence of Rai1 gene 
haploinsufficiency.  Rai1
+/- mutants also had an abnormal 
electroencephalogram with overt seizures observed in ap-
proximately 2% of the generated mice. These mice exhibited 
normal locomotor activity, in a mixed genetic background, in 
clear contrast, mice with smaller deletion (~590 kb genomic 
interval) and the Df(11)17 mice that shown hypoactivity in 
the open field test [75]. However, when Rai
+/- mice where 
tested in a different genomic background the hypoactivity 
phenotype was recovered indicating that Rai1 is involved in 
these phenotype but is clearly influenced by modifiers [71].  
 Homozygous  Rai1
-/- mice displayed a more severe phe-
notype, presenting malformations in both craniofacial and 
the axial skeleton. Neurobehavioral abnormalities including 
hind limb clasping, overt seizures in 1/3 of the mutant mice, 
motor impairment, and context and tone dependant learning 
deficits were also present in these mice [68, 75]. Another 
advantage of this mouse model was that the reporter lacZ 
gene was knocked-in the Rai1 locus making it possible to 
study the expression patterns of Rai1 during the embryo-
genesis and adulthood. When the blue staining, resulting 
from the -galactosidase activity, indicative of Rai1 gene 
expression was studied during embryogenesis it was found 
that at 9.5 dpc Rai1 is expressed mainly in branchial arches 
and otic vesicles. Postnatal studies showed low levels of ex-
pression throughout the brain, being most predominantly 
expressed in the hippocampus and the cerebellum. In addi-
tion to the brain, Rai1 expression was found in thymus, 
bronchioles of the lung, collecting tubules in the kidney, the 
testis, the epididymis, and the ovaries, the hair follicles in the 
skin, the tongue, the mandibular gland and the intestine [75]. 
Another important finding obtained from this model is that 
Rai1 has an important participation in embryonic develop-
ment, since Rai1
-/- mice presented impaired viability, and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Existing mouse models of SMS and PTLS syndromes. A) Schematic representation of the wild type 32-34 cM region of 11 
mouse chromosome (black line, Mouse 32-34 cM) and the different deletions available at the present (black-grey doted line). The SMS criti-
cal region (Df(11)17) [65] and the smaller deletions (Df(11)17-1, -2, -3) [67] are depicted. Finally the mouse harboring a LacZ knock-in in 
the Rai1 coding sequence is illustrated with a light grey triangle (LacZ knock-in) [68]. B) Representation of the two murine models for the 
PTLS, one carrying the duplication of the SMS critical region in 11 chromosome 32-34 cM (dark grey line)[65] and a BAC transgenic mouse 
containing the Rai1 gene [69]. The sizes of the rearrangements are specified within parenthesis. 264    Current Genomics, 2009, Vol. 10, No. 4  Carmona-Mora et al. 
growth retardation of the survived mice [68]. Moreover, the 
Rai
+/- survival rate was found to be dependent of genetic 
background [76] something that was also observed for the 
Df(11)17/+ mice [77]. 
  In a first attempt to identify the gene responsible for the 
PTLS a study was carried out with Dp(11)17/Rai1
- com-
pound heterozygous mice, since both mouse models were 
already available. By mating Dp(11)17/+ mice with Rai1
+/- 
animals we were able to analyze Dp(11)17/+,  wild type, 
Rai1
+/- and Dp(11)17/Rai1
- mice and explore the role of Rai1 
copy number in the Dp(11)17/+ phenotype [53]. The genera-
tion of Dp(11)17/Rai1
- compound heterozygous animals, 
determined that restoring the 2n gene dosage of Rai1 alone is 
sufficient to rescue part of the phenotypes observed in the 
PTLS mouse model (weight, anxiety and learning difficul-
ties), despite the trisomic copy number of the remaining 18 
genes in the SMS critical interval (Table 2) (Fig. (4)). Thus, 
it was demonstrated that Rai1 was the gene whose CNV 
within this genomic interval was responsible for several 
complex physical and behavioral traits. However, is impor-
tant to point out here that not all the phenotypes observed in 
the Dp(11)17/+ mice were rescued by the correction of Rai1 
gene dosage (see below). 
  Years later, and reinforcing the concept that Rai1 was the 
dosage sensitive gene responsible for PTLS, transgenic mice 
containing four or five additional copies of Rai1 were gener-
ated and tested for assessing physical, neurological and be-
havioral phenotypes. These transgenic mice were signifi-
cantly underweight and got smaller head and body sizes 
when compared with their wild type littermates. Hyperactiv-
ity, increased anxiety in the open field and a dominant be-
havior in the tube test for social interaction evaluation were 
Table 2.  Phenotypes Present in Mice with the Complete Gene Dosage Corrected within this Genomic Interval (Dp(11)17/Df(11)17) 
or Only Rai1 Gene Dosage Corrected (Dp(11)17/Rai1
-) Compared to Dp(11)17/+ and Df(11)17/+ Mice 
Phenotype  Dp(11)17/+  Df(11)17/+ Dp(11)17/Df(11)17  Rai1
+/- Dp(11)17/Rai1
- 
Body weight  Reduced Higher  Normal  Higher  Normal 
Overt seizures  Absent Present  (20%) Absent  Subtle  (2%)  Absent 
EEG  Normal Abnormal  Abnormal Abnormal  ND 
Locomotor activity  Hyperactive Hypoactive Hyperactive  Normal/Hypoactive(***)  Hyperactive 
Anxiety  Increased* Decreased* Decreased*  Normal**  Normal** 
 Learning and memory  Impaired Normal  Normal  Normal  Normal 
Citation  [65, 70]  [65, 70]  [53, 65]   [53, 68, 75]  [53] 
(*) Phenotype was tested by plus maze test (data non published), (**) open field. 
(***) Depending on the genetic background. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Contribution of existing mouse models for SMS and PTLS. The contribution of the study of the existing SMS and PTLS mouse 
models in the understanding of the phenotypic and molecular consequences of genomic disorders.  Mouse Models of Genomic Syndromes  Current Genomics, 2009, Vol. 10, No. 4    265 
also observed in the transgenic mice. Abnormal maternal 
behavior, altered sociability, and impaired serotonin metabo-
lism in Rai1- BAC transgenic mice with a dosage-dependent 
worsening of the phenotype while increasing copies of Rai1, 
was also reported [69, 78].  
  As was previously described most but not all phenotypes 
were rescued in the Dp(11)17/Rai1
- mice. This prompted to 
the evaluation of Dp(11)17/Df(11)17 phenotype. Since the 
same genomic region is deleted and duplicated, these mice 
represented a unique tool in order to study the consequences 
of restoring the correct gene copy number within the inter-
val, albeit in a uniallelic fashion. All these experiments were 
performed in an inbred genetic background. Essentially the 
same battery of experiments for assessing the phenotypes 
before mentioned, were tested in mice with 1n (Df(11)17/+), 
2n (wild type and Dp(11)17/Df(11)17), or 3n (Dp(11)17/+) 
copies of the genes within the critical genomic interval. It 
was found that craniofacial abnormalities observed for 
Df(11)17/+ were completely rescued in Dp(11)17/Df(11)17 
mice, demonstrating that this phenotype is due to the hap-
loinsufficiency of the genes deleted within the SMS region. 
This dosage restoration also rescued the differences of body 
weight between Df(11)17/+ and Dp(11)17/+ mice, since the 
animals Dp(11)17/Df(11)17 have wild type weight curves. 
The behavioral traits of Dp(11)17/Df(11)17  progeny, in 
which the dosage of all 19 genes in the SMS critical interval 
is balanced, were mostly normalized (seizures, anxiety, 
learning and memory) (Table 2), indicating that gene dosage, 
more than positional effects, influences behavior. This is true 
for most of the phenotypes, however, the hyperactivity 
shown in the open field by Dp(11)17/+ mice was not rescued 
in Dp(11)17/Df(11)17 mice [53]. In conclusion, phenotypic 
assessment of Dp(11)17/Df(11)17 animals, in a pure genetic 
background, demonstrate that some phenotypes observed in 
CGS are due by “dosage effect” but others are a consequence 
of “positional effect”, uncoupling, for the first time, the ef-
fects of gene CNV and genomic structural changes and high-
light the delicacy of genomic control mechanisms [53, 77].  
  Another interesting aspect that can be addressed by 
studying these mouse models is the influence of structural 
changes on the transcription of genes within and outside the 
rearranged interval. It was previously reported that the ane-
uploid genes and also the flanking genes that map up to sev-
eral megabases away from the rearranged interval are af-
fected in their relative expression level for the human chro-
mosome 7 DNA deletion that causes Williams-Beuren syn-
drome [79]. By the study of the hippocampus transcriptome 
of Dp(11)17/+ male mice compared to their normal litter-
mates by real time PCR and DNA microarrays, [71] it was 
found that not only the genes included in the genomic rear-
ranged region, but also normal copy number genes that 
flanked the engineered interval showed altered (up or down) 
expression levels in the hippocampus of Dp(11)17/+ mice. 
Analysis of the transcriptome of Df(11)17/Dp(11)17 mice is 
underway, but preliminary data shows that these “flanking” 
effects are unidirectional and uncoupled from the number of 
copies of the CNV genes (personal communication). Thus, 
these results indicate that a structural change at a given posi-
tion of the genome may cause the same perturbation in par-
ticular pathways regardless of gene dosage. Moreover, re-
sults reported in wild mice and classical inbred strains where 
a CNV map was generated and the genome-wide expression 
data from six major organs was compared showed that not 
only the expression of genes within CNVs tend to correlate 
with copy number changes, but also that CNVs influence the 
expression of genes in their vicinity, an effect that extends 
up to half a megabase [80, 81]. Taken these results altogether 
suggest that this kind of genomic variation plays a general 
role in the phenotypic outcome.  
  In summary, although extensive research on CNV is 
taken place in a genomic context, mouse models have prove 
to be an efficient and unique tool to unravel the phenotypic 
and molecular consequences of genomic disorders. These 
advantages includes more specific aspects related to the syn-
dromes to which they are associated as the discovery of dos-
age sensitive genes, the definition of the phenotypic conse-
quences of the rearrangement, the study of the function of 
genes affected by CNV and their participation in a specific 
phenotype to more general aspect as the contribution in the 
understanding of the effects of CNV in a genomic context.  
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